Plain-English translation of NCT07106736 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a fully personalized treatment strategy for newly diagnosed multiple myeloma in patients who are not eligible for or prefer to avoid stem cell transplant. The study uses cell therapy—a type of immunotherapy that trains your own immune cells to fight myeloma—and may add other immune therapies depending on how your disease responds. Your treatment plan will be customized based on your cancer's specific genetic features and how well it responds to therapy.
Many patients with multiple myeloma cannot tolerate or choose to avoid stem cell transplant due to age or other health concerns. This trial aims to provide a highly effective alternative using advanced immunotherapy approaches that adapt based on each patient's individual cancer biology and treatment response.
You likely qualify if…
You likely don't qualify if…
You will first receive standard chemotherapy induction therapy (up to four cycles) to treat your myeloma. After that, you will receive the cell therapy infusion. Depending on how your cancer responds and your risk category, you may receive additional consolidation and maintenance treatments. Throughout the study, your doctors will monitor your cancer response through blood tests and imaging. If your cancer goes into a deep remission and stays stable, you may eventually enter a treatment-free observation phase, resuming therapy only if your cancer shows signs of returning.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China